Florian Heitz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3550408/publications.pdf

Version: 2024-02-01

44	2,716	279487	243296
papers	citations	23 h-index	44 g-index

47	47	47	5868
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
2	Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience. Gynecologic Oncology Reports, 2022, 40, 100939.	0.3	7
3	Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer. PLoS ONE, 2022, 17, e0262770.	1.1	3
4	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
5	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancerâ€”Impact for Diagnosis and Treatment Monitoring. Cancers, 2022, 14, 168.	1.7	5
6	Clonal Hematopoiesisâ€“Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 565-570.	3.0	17
7	Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). British Journal of Cancer, 2022, 126, 1047-1054.	2.9	17
8	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
9	Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	1.1	5
10	Dilution of Molecularâ€“Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. Clinical Cancer Research, 2020, 26, 213-219.	3.2	12
11	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	3.2	41
12	Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecologic Oncology, 2020, 157, 411-417.	0.6	30
13	Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery. Gynecologic Oncology, 2019, 154, 577-582.	0.6	8
14	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecologic Oncology, 2019, 152, 235-242.	0.6	10
15	Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Annals of Surgical Oncology, 2018, 25, 2053-2059.	0.7	36
16	ASO Author Reflections: Systematic Lymph Node Dissection in Ovarian Cancer Under Attack. Annals of Surgical Oncology, 2018, 25, 884-885.	0.7	1
17	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
18	Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecologic Oncology, 2017, 144, 181-186.	0.6	22

#	Article	IF	Citations
19	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	1.1	105
20	Response to the letter of Fagotti et al. regarding the manuscript: â€œPattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgeryâ€• Gynecologic Oncology Reports, 2016, 18, 55-56.	0.3	1
21	Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer. Annals of Surgical Oncology, 2016, 23, 834-840.	0.7	29
22	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
23	Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 1594-1600.	1.2	23
24	Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecologic Oncology, 2016, 141, 264-270.	0.6	46
25	Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic Oncology, 2016, 140, 457-462.	0.6	159
26	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
27	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
28	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
29	Synchronous Ovarian and Endometrial Cancerâ€”an International Multicenter Case-Control Study. International Journal of Gynecological Cancer, 2014, 24, 54-60.	1.2	52
30	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	0.6	55
31	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
32	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
33	Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancerâ€”a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecologic Oncology, 2013, 129, 463-466.	0.6	37
34	Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. American Journal of Obstetrics and Gynecology, 2013, 209, 592-593.	0.7	6
35	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
36	Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity. Clinical Cancer Research, 2012, 18, 2632-2637.	3.2	4

#	Article	IF	Citations
37	Bevacizumab in the Treatment of Ovarian Cancer. Advances in Therapy, 2012, 29, 723-735.	1.3	33
38	Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecologic Oncology, 2011, 121, 615-619.	0.6	166
39	Surgery for Recurrent Ovarian Cancer. Women's Health, 2011, 7, 529-535.	0.7	6
40	Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Review of Anticancer Therapy, 2010, 10, 81-88.	1.1	46
41	Abdominal Wall Metastases in Patients With Ovarian Cancer After Laparoscopic Surgery. International Journal of Gynecological Cancer, 2010, 20, 41-46.	1.2	37
42	Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Review of Anticancer Therapy, 2010, 10, 1125-1136.	1.1	35
43	Role of cytoreductive surgery in recurrent ovarian cancer. Expert Review of Anticancer Therapy, 2009, 9, 917-922.	1.1	12
44	Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. European Journal of Cancer, 2009, 45, 2792-2798.	1.3	190